PET: Radiotracer List 2020

RDRC Approved Drug Master File in Place (Currently Available in PET Formulary)
RDRC Approved Drug Master File in Place (Not currently Available in PET Formulary)
FDA-approved IND Chemistry, Manufacturing and Control Documentation
FDA IND Chemistry, Manufacturing and Control Documentation (in process)

RDRC Approved Drug Master File in Place (Currently Available in PET Formulary)

AgentTarget
[11C]PBR-28 TSPO, aka peripheral benzodiazepine receptor
[11C]DASB serotonin transporter
[11C]CUMI-101 serotonin 5-HT1A receptor agonist
[11C]DTBZ VMAT2 vesicular monoamine transporter
[11C]CFT dopamine transporter
[11C]FLB457 dopamine D2/D3 receptor
[11C]raclopride (dopamine D2/D3 receptor)
[11C]NPA dopamine D2 receptor agonist
[11C]NOP-1A nociceptin/orphanin FQ peptide receptor
[11C]UCB-J SV2A
[11C]PIB β-amyloid
[18F]FDG glucose metabolism
[18F]MK 6240 τ-Requires prospective protocol approval by Cerveau
[18F]BCPP-EF mitochondrial complex I-Use requires prospective protocol approval by Hamamatsu)

RDRC Approved Drug Master File in Place (Not currently Available in PET Formulary)

Available upon Request- Contact Head of Radiochemistry

AgentTarget
[15O]H2O perfusion
[15O]O2 oxygen metabolism
[13N]Ammonia myocardial blood flow
[18F]FMISO hypoxia
[11C]3-O-methylglucose glucose transport
[11C]PMP acetylcholinesterase substrate
[18F]FLT thymidine kinase substrate
[18F]ML10 apoptosis
[11C]flumazenil central benzodiazepine receptor
[11C]PK-11195 TSPO, aka peripheral benzodiazepine receptor
[carbonyl-11C]WAY-100635 serotonin 5-HT1A receptor
[11C]fallypride dopamine D2/D3 receptor
[18F]altanserin serotonin 5-HT2A receptor
[11C]IMA107 PDE10A
[68Ga]PRGD2 integrin αVβ3
[11C]McN5652X and W serotonin transporter
[18F]FNOS inducible nitric oxide synthase

FDA-approved IND Chemistry, Manufacturing and Control Documentation

AgentTarget
[18F]AV1451 τ-Use requires prospective protocol approval by Lily/Avid
[11C]ABP 688 metabotropic glutamate receptor subtype 5-IND inactive
[18F]FDOPA AADC substrate-Sponsored study Voyager Therapeutics
[11C]PIB β-amyloid
[18F]flutemetamol β-amyloid-IND inactive
[18F]2'FPiB β-amyloid-IND inactive
[18F]2’F-BiP** β-amyloid-IND inactive
(**[18F]-2’F-4’-HO-6-MeNHBT)
[18F]FAraG Activated T cells- Use requires prospective protocol approval by CellSight, LLC.
[18F]BMS-986192 PD-L1 expression- Use requires prospective protocol approval by Bristol-Myers Squibb
[64Cu]LLP2A Very Late Antigen-4 (VLA-4)

FDA IND Chemistry, Manufacturing and Control Documentation (in process)

AgentTarget